The first vector
out of the loop.
Engineered exosomes are the first delivery vector the ExoAI stack ships. Nano-vesicles released by every cell, they cross barriers other vehicles can't, evade the immune system, and home to specific tissues by surface chemistry. We isolate them, load them, and route them — across organs, on demand.
One carrier chassis. Tunable tropism. Programmable cargo.
cGMP MSC-derived exosomes, characterized by CD9/CD63/CD81 and nanoparticle tracking. Scalable, donor-agnostic production.
Surface-display ligands (RVG, RGD, ApoE, antibody fragments) tune tropism to the target cell type. Cargo loaded by electroporation or sonication.
Delivery route matched to target tissue — intranasal, IV, intratumoral, intramuscular. The carrier does the targeting.
One platform, every tissue address.
Intranasal route + olfactory tropism for CNS-adjacent delivery.
Hepatocyte uptake via natural ApoE / LDLR display — IV route.
Cardiomyocyte-tropic MSC exosomes for post-ischemic repair.
Engineered RGD / iRGD display for solid-tumor homing.
DC and T-cell targeting for vaccine and immunotherapy cargo.
Tubular epithelium uptake for AKI and CKD payloads.
Exosomes are the fastest path to a clinic-ready vector — nature's targeted nanocarrier, low immunogenicity, tunable tropism. They're the first output of the ExoAI stack and the proof the loop works. In parallel, the agents are designing the next vector: synthetic LNPs that match exosome-grade targeting at scalable manufacturing.